© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Biocon to go Ahead with Syngene IPO, Listing Likely in July
Posted 19th May 2015

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biotechnology major Biocon on Wednesday filed a prospectus with market regulator Securities and Exchange Board of India (Sebi) for the Initial Public Offer (IPO) of its research arm, Syngene, through which it aims to raise around Rs 600 crore for funding research and development (R&D).

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biocon to go Ahead with Syngene IPO, Listing Likely in July

View Biography
Amarchand & Mangaldas

Biopharmaceuticals major Biocon on Tuesday said that the unlocking of the value from its contract research subsidiary Syngene would help the company fund its research and development programmes.

Syngene has already filed the draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), seeking approval for an initial public offering (IPO). The company is estimated to be raising around Rs 600 crore through this public issue.

“We are unlocking value from Syngene to fund our R&D programmes, which include a rich pipeline of biosimilars and novel biologics. This fund infusion will help accelerate these programmes which are at various stages of development currently,” said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL), currently holds an 84.5 per cent equity stake in Syngene. The company is offering to sell up to 22 million equity shares of face value of Rs 10 each, through Syngene’s IPO.

The offer includes a reservation of two million equity shares for Biocon’s public equity shareholders, being individuals and Hindu Undivided Families (HUFs). The offer would constitute 11 per cent of the post offer paid-up equity share capital of the company.

Established in 1993, Syngene offers a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. The company’s service offerings also support the development of biosimilar and generic molecules.

During the nine months period-ended December 31, 2014, Syngene serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014.

Syngene had reported revenues of Rs 707.7 crore for the previous financial year-ended March 31, 2014 and Rs 617.5 crore for the nine months period ended December 31, 2014. Earlier this month, the company appointed Peter Bains as its Chief Executive Officer. Bains has been a part of Syngene since January 2010 as a director and has more than two decades of experience in the pharmaceutical space.

“Syngene has a proven track record of providing quality NME discovery, development and manufacturing services. It has long-standing partnerships with three of the world’s leading global healthcare organisations, including Bristol-Myers Squibb Co. and has attracted equity participation from India Value Fund recently, which is reflective of the scale, the value and the quality of the differentiated business model of Syngene,” added Mazumdar-Shaw.

Categories: Finance


You Might Also Like
Read Full PostRead - Eye Icon
Taking The Right Approach To Due Diligence When Acquiring A Business: Key Steps To Success
Legal
19/02/2020Taking The Right Approach To Due Diligence When Acquiring A Business: Key Steps To Success

Whilst not the most glamorous part of the process, due diligence is a key element of any acquisition. When expanded beyond a simple tick box exercise, due diligence can go a long way in determining the success of an acquisition. How can buyers successfully app

Read Full PostRead - Eye Icon
How Much of Your Income Should You Save Every Month?
News
21/06/2022How Much of Your Income Should You Save Every Month?

Image Source: Unsplash From luxurious holidays to fancy cars, we all want to live our lives to the fullest while we’re young, but our lifestyles shouldn’t come at the cost of retirement. Our financial safety nets can also help us prepare for emergencies an

Read Full PostRead - Eye Icon
Third Quarter Update
Legal
02/02/2016Third Quarter Update

DN Legal is a legal firm dedicated to providing bespoke legal services tailored to the client’s individual needs.

Read Full PostRead - Eye Icon
Longstanding Xero Director Launches Libeo in the UK
Leadership
12/05/2022Longstanding Xero Director Launches Libeo in the UK

With the leadership of newly appointed Glen Foster, Managing Director for the UK and Northern Europe, the move will be powered by Libeo’s competitive advantage and its innovative differentiating features.

Read Full PostRead - Eye Icon
Why Copy Trading is Not a Sure Win Strategy
Finance
09/05/2022Why Copy Trading is Not a Sure Win Strategy

Novice investors often look to copy trading as a sure win strategy to get a good return on investment (ROI). By following the market movements of successful traders with high-performing investments, they hope to be as successful as the traders they follow on c

Read Full PostRead - Eye Icon
Wave Goodbye to the  Zimbabwean Dollar
Finance
13/07/2015Wave Goodbye to the Zimbabwean Dollar

The Zimbabwe government has announced it will officially discard the Zimbabwean dollar. Hyper-inflation had rendered it near worthless, making the US dollar the most widely used currency.

Read Full PostRead - Eye Icon
China’s Crisis Poses Major Threat to Global Economy, Says IMF
Finance
08/09/2015China’s Crisis Poses Major Threat to Global Economy, Says IMF

China's slowdown in economic growth may have further repercussions for the global economy, the International Monetary Fund has warned.

Read Full PostRead - Eye Icon
TPG and Leonard Green & Partners Acquire Life Time Fitness for USD4b
Finance
Read Full PostRead - Eye Icon
WKB Advise Aviva During Acquisition of Expander Advisors
Legal
15/07/2015WKB Advise Aviva During Acquisition of Expander Advisors

WKB Advise Aviva During Acquisition of Expander Advisors



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow